Document:

Form of Investor Purchase Agreement

 Exhibit 10.2 
 FORM OF INVESTOR PURCHASE AGREEMENT 
 July 14, 2008 
 Pharmasset, Inc. 
 303-A College Road East, 
 Princeton, NJ 08540 
 Ladies and Gentlemen: 
 The undersigned (the “Investor”), hereby confirms and agrees with you as follows: 
 1. This Investor Purchase Agreement (the “Agreement”) is made as the date hereof between Pharmasset, Inc., a Delaware corporation (the
“Company”), and the Investor. 
 2. The Company has authorized the sale and issuance to certain investors of up to shares
(the “Shares”) of its Common Stock, par value $0.001 per share (the “Common Stock”), for a purchase price of $             per share (the
“Purchase Price”) (collectively, the “Offering”). All defined terms used herein and not otherwise defined shall have the same meanings ascribed to such terms in the Placement Agency Agreement dated the date hereof
by and among the Company and the Placement Agents named therein (the “Placement Agency Agreement”). 
 3. The Company and
the Investor agree that the Investor will purchase from the Company, and the Company will issue and sell to the Investor, the number of Shares set forth below for the aggregate purchase price set forth below, pursuant to and subject to the Terms and
Conditions for Purchase of Shares attached hereto as Annex I. Unless otherwise requested by the Investor and agreed to by the Company, the Shares purchased by the Investor will be delivered by electronic book-entry, registered in the
Investor’s name and address as set forth below and will be released by Computershare, the Company’s transfer agent (the “Transfer Agent”), to the Investor at the Closing (as defined in the Terms and Conditions for Purchase
of Shares). 
 4. The Investor confirms that it has had full access to all filings made by the Company with the Securities and Exchange
Commission (the “SEC”), including the Registration Statement and any Free Writing Prospectus, and that it was able to read, review, download and print each such filing. On or promptly following the date hereof, the Company will file
a prospectus supplement with the SEC containing certain supplemental information regarding the Company and the Offering. 
 [Remainder of
page intentionally left blank. Signature pages follow.] 

 Number of Shares: 
 Aggregate Purchase Price: $ 
 Please confirm that the foregoing correctly sets forth the agreement between us by signing in the
space provided below for that purpose. 
  

					
		 	AGREED AND ACCEPTED:
		
	Name of Investor:	 	 
			
		 	By:	 	 
			
		 	Name:	 	 
			
		 	Title:	 	 

 [Signature Page to Investor Purchase Agreement] 
  

 - 2 - 

			
	PHARMASSET, INC.
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 

 [Signature Page to Investor Purchase Agreement] 
  

 - 3 - 

 ANNEX I 
 TERMS AND CONDITIONS FOR PURCHASE OF SHARES 
 1. Closings and Delivery of the Shares and Funds. 
 1.1. Closing. The completion of the purchase and sale of the Shares (the “Closing”) will occur at a place and time (the
“Closing Date”) to be specified by the Company and the Placement Agents, and of which the Investors will be notified in advance by the Placement Agents. At the Closing, (a) the Company will cause the Transfer Agent to deliver
to the Investor the number of Shares set forth on the signature page hereto registered in the name of the Investor or, if so indicated on the Stock Certificate Questionnaire attached hereto as Exhibit A, in the name of a nominee designated by
the Investor and (b) the aggregate purchase price for the Shares being purchased by the Investor will be delivered by or on behalf of the Investor to the Company. 
 1.2. Delivery of Funds. On the Closing Date, the Investor shall remit by wire transfer the amount of funds equal to the aggregate purchase price for the Shares being purchased by the Investor to the
following account designated by the Company 
  

			
	Citibank N.A.	  	
	ABA Routing No.:	  	 [                    ]

	FBO:	  	 [                    ] 

	Citigroup Account No.:	  	 [                    ] 

		
	Further Credit to Citigroup Client:	  	
	Account Name:	  	 [                    ] 

	Account Number:	  	 [                    ] 

		
	Swift Code:	  	 [                    ] 

		  	(if transferring from a foreign country)
		
	Bank Address:	  	 [                    ] 

		  	 [                    ] 
 [                    ]

		
	Bank Contact:	  	 [                    ] 

	Tel No.:	  	 [                    ] 

 1.3. Delivery of Shares. On the Closing Date, the Investor shall direct the
broker-dealer at which the account or accounts to be credited with the Shares are maintained, which broker/dealer shall be a DTC participant, to set up a Deposit/Withdrawal at Custodian (“DWAC”) instructing the Transfer Agent to
credit such account or accounts with the Shares by means of an electronic book-entry delivery. Such DWAC shall indicate the settlement date for the deposit of the Shares, which date shall be provided to the Investor by the Placement Agents. Upon
receipt of the funds by the Company, the Company shall direct the Transfer Agent to credit the Investor’s account or accounts with the Shares pursuant to the information contained in the DWAC. 

 2. Changes. This Agreement may not be modified or amended except pursuant to an instrument in writing
signed by the Company and the Investor. 
 3. Headings. The headings of the various sections of this Agreement have been inserted for
convenience of reference only and will not be deemed to be part of this Agreement. 
 4. Severability. In case any provision contained in this
Agreement should be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein will not in any way be affected or impaired thereby. 
 5. Governing Law. This Agreement will be governed by, and construed in accordance with, the internal laws of the State of New York, without giving effect to the
principles of conflicts of law that would require the application of the laws of any other jurisdiction. 
 6. No Third-Party Beneficiary.
Nothing in this Agreement is intended or shall be construed to give the Investor any legal or equitable right, remedy or claim under or in respect of the Placement Agency Agreement or any provision contained therein. 
 7. Counterparts. This Agreement may be executed in two or more counterparts, each of which will constitute an original, but all of which, when taken
together, will constitute but one instrument, and will become effective when one or more counterparts have been signed by each party hereto and delivered to the other parties. 
  

 - 2 - 

 EXHIBIT A 
 PHARMASSET, INC. 
 STOCK CERTIFICATE QUESTIONNAIRE 
 Pursuant to Section 1 of the Agreement, please allocate the Shares as follows: 
  

			
	 ACCOUNT NAME
	  	SHARES
		  	
	TOTAL	  	

  

 - 3 -Amendment dated July 16, 2007 to Employment Agreement

 Exhibit 10.1 
 AGREEMENT 
 This Agreement is entered into and effective this 16th day of July, 2007, by and between
Cryo-Cell International, Inc. (the “Company”) and Mercedes Walton (the “Executive”). 
 RECITALS 
 A. The Company and the Executive entered into an Employment Agreement dated August 15, 2005 (the “Employment Agreement”) pursuant to which
the Company agreed to provide certain specified compensation to the Executive. 
 B. The Company and the Executive desire to amend the terms
of the Executive’s Employment Agreement to comply with Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) as provided herein. 
 NOW, THEREFORE, in consideration of the foregoing and the mutual covenants contained herein, the parties agree, and the Employment Agreement hereby is amended, as follows: 
 AMENDMENT 
 1. The following sentence
is hereby added at the end of subparagraph 2(f) of the Employment Agreement: 
 “Any such reimbursement shall be for
expenses incurred by the Executive during her lifetime and such reimbursement shall be made not later than December 31 of the year following the year in which the Executive incurs the expense. In no event will the amount of expenses so
reimbursed by the Company in one year affect the amount of expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year.” 
 2. The last sentence of subparagraph 3(e)(ii) of the Employment Agreement is hereby deleted in its entirety and replaced with the following: 
 “Such payments shall be made in a lump sum on the earlier of (A) the first day of the seventh month following the Executive’s
“separation from service” with the Company (as such phrase is defined in Section 409A of the Code) (the “Separation from Service”) or (B) the Executive’s death, together with interest thereon from the date of such
Separation from Service through the date of payment at the applicable federal rate, determined under Section 1274(d) of the Code. 
 3.
The following language is hereby inserted at the end of subparagraph 3(e)(iii) of the Employment Agreement: 
 “; provided that either
the provision and payment of any benefits under such plans or programs is excluded from the phrase “deferral of compensation” (as such phrase is defined for purposes of Section 409A of the Code) or the value of the provision and
payment of any such benefits that are not so excluded in the aggregate do not exceed the applicable dollar amount under Section 402(g)(1)(B) of the Code for the year of Executive’s Separation of Service.” 

 4. Subparagraph 3(e)(iv) of the Employment Agreement is hereby deleted in its entirety and replaced with
the following: 
 “The Company shall pay all reasonable legal fees and expenses incurred by the Executive during her lifetime as a result
of such termination, including the legal fees and expenses of enforcing the terms of this Agreement; payment of such fees shall be made within thirty (30) days following the Company’s receipt of an appropriate invoice therefor, but not
later than December 31 of the year following the year in which the Executive incurs such fees and expenses. In no event will the amount of fees and expenses so paid by the Company in one year affect the amount of fees and expenses that the
Company is obligated to pay, or in-kind benefits to be provided, in any other taxable year.” 
 5. The following language is hereby
inserted at the end of subparagraph 3(e)(v) of the Employment Agreement: 
 “; provided, however, that all such
outplacement services must be completed, and all payments by the Company must be made, by December 31 of the second calendar year following the calendar year in which the Executive’s Separation from Service occurs.” 
 6. The third and fourth sentences of subparagraph 3(e)(vii)(A) of the Employment Agreement are hereby deleted in their entirety and replaced with the
following sentence: 
 “If the Present Value of such “parachute payments” equals or exceeds the Parachute Limit, but does not
exceed 105% of the Parachute Limit, then the lump sum cash severance payment described in Section 3(e)(ii) shall be reduced such that the “parachute payments” are one dollar ($1.00) less than the Parachute Limit.” 
 7. The following language is hereby inserted at the end of subparagraph 10(b)(ii) of the Employment Agreement: 
 “, and thereafter interpret its provisions in a manner that complies with Code Section 409A. Reference to Section 409A of the Code is to
Section 409A of the Internal Revenue Code of 1986, as amended, and will also include any proposed, temporary or final regulations, or any other guidance, promulgated with respect to such Section by the U.S. Department of the Treasury or the
Internal Revenue Service.” 
  

 -2- 

 8. A new subparagraph 10(g) is hereby added to the end of paragraph 10 of the Employment Agreement as
follows: 
 “g. Effect of Provisions 
 To the extent that the Executive’s employment is terminated upon or within two (2) years after a Change of Control,
subparagraphs 3(a), 3(b), 3(c), 3(f) and 3(g) shall have no further force and effect and shall no longer be operative. 
 9. The following
language is hereby inserted at the end of subparagraph (d) of Exhibit A as follows: 
 “Notwithstanding the
foregoing, in all events, no Gross-Up Payment will be made prior to the first day of the seventh month following the Executive’s Separation from Service and all Gross-Up Payments will be made no later than December 31 of the year following
the Executive’s taxable year in which the Executive remits the taxes giving rise to the Gross-Up Payment.” 
 10. The parties agree
that this Agreement amends the Employment Agreement and that, except as amended herein, the Employment Agreement shall remain unchanged and in full force and effect. 
 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above. 
  

			
	CRYO-CELL INTERNATIONAL, INC.
		
	By:	 	 /s/ Jill Taymans

	Name:	 	Jill Taymans
	Title:	 	VP Finance/CFO
	
	 /s/ Mercedes Walton

	Executive

  

 -3-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00144-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00144-of-00352.parquet"}]]